Add Company
Join Now

BioMagnetic Solutions Revenue and Competitors

License our Company Data API

State College, PA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • BioMagnetic Solutions's estimated annual revenue is currently $3.4M per year.(i)
  • BioMagnetic Solutions's estimated revenue per employee is $155,000

Employee Data

  • BioMagnetic Solutions has 22 Employees.(i)
  • BioMagnetic Solutions grew their employee count by 5% last year.

BioMagnetic Solutions's People

NameTitleEmail/Phone
1
Chief Commercial Officer (CCO) & Co-FounderReveal Email/Phone
2
Chief Operating OfficerReveal Email/Phone
3
Chief Scientific OfficerReveal Email/Phone
4
Director QualityReveal Email/Phone
5
Director, Account and Market DevelopmentReveal Email/Phone
6
Director Marketing And Product ManagementReveal Email/Phone
7
Laboratory ManagerReveal Email/Phone
8
Senior Quality SpecialistReveal Email/Phone
9
Project EngineerReveal Email/Phone
10
Manufacturing EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is BioMagnetic Solutions?

BioMagnetic Solutions (BioMag) is launching X-GRAFFE system, a state of the art immunomagnetic Cell Selection system for CAR-T cell & Gene Therapy (CGT) product mfg. X-GRAFFE will revolutionize the CGT cell selection process with its ultra high-performance, very rapid, gentle process & clean sheet of paper design & mkt. proven Ferrofluids. BioMag's X-GRAFFE Clinical-Scale Cell Selection system & nano-magnetic ferrofluids very rapidly yet very gently isolate cell subsets for CAR-T cell & gene therapy (GT) product mfg. X-GRAFFE is an elegant, closed system w/an array of patent-pending protocols & hardware. X-GRAFFE isolates CD34+ stem cells for GT & cell processing mfg. BioMag partners for its complementary array of cGMP mAbs, cytokines & CGT mfg. reagents. Founded in 2012 by Paul A. Liberti, PhD, BioMagnetic Solutions has a 30+ year history pioneering immuno-magnetic cell selection systems. Prior to BioMag, Liberti founded Immunicon (NASDAQ: IMMC) where he developed the Ferrofluids & immunomagnetic systems for CELLSEARCH® - the only FDA-approved Circulating Tumor Cell (CTC) assay that J&J/Janssen acq'd in 2008. BioMag's X-GRAFFE system leverages BioMag's market-tested** proprietary 6th-gen immunomagnetic Ferrofluids. BioMag also provides an array of proprietary cell selection reagents to the research market to scientists worldwide. Having pioneered Ferrofluid development & the design & mfg. of novel magnetic platform technologies for cell selection via our Immunicon DNA, BioMag brings 30+ cutting-edge R&D problem-solving years, IP & innovation to the design, synthesis & manufacture of Ferrofluids for path-breaking novel multi-parameter bio-magnetic selection systems. * CELLSEARCH® remains the only FDA-approved CTC assay for isolating & characterizing CTC - **16 years since its 2004 Immunicon introduction. CELLSEARCH© was acquired by J&J's Janssen Oncology SBU (formerly J&J's Veridex SBU). CELLSEARCH® is now owned by Menarini's Silicon Biosystems (2018).

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.2M22-42%N/A
#2
$2.2M22-19%N/A
#3
$3.6M230%N/A
#4
$3.4M23-8%N/A
#5
$2.4M2321%N/A